There are currently 1094 clinical trials in Rochester, Minnesota looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic, Mayo Clinic in Rochester, Mayo Clinic - Rochester and Mayo Clinic Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Sleep Restriction and Parental History of Hypertension
NCT06482814
Recruiting
The purpose of this study is to research the effects of partial sleep deprivation (sleep restriction) in a group of individuals whose parents have high blood pressure compared to a group of individuals whose parents have normal blood pressure.
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
07/30/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Hypertension
Register for Updates
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
NCT00271180
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: Not set, Rochester, Minnesota
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Register for Updates
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
NCT05103683
Recruiting
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
Register for Updates
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
NCT05001880
Recruiting
This phase II trial compares the usual treatment alone (carboplatin, pemetrexed, and bevacizumab) to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma. The usual treatment consists of surgery or chemotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slow... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Peritoneal Malignant Mesothelioma
Register for Updates
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
NCT04069273
Recruiting
Cohort 1 \[CLOSED\] Study treatment involves two segments: (1) Induction Immunotherapy segment with pembrolizumab monotherapy every 3 weeks until irRECIST PD and (2) Combination Therapy segment. Nab-paclitaxel may be utilized in place of paclitaxel at investigator's discretion for subjects with paclitaxel reactions. Cohort 2 Patients are randomized to Arm A or B. Treatment in both arms includes pembrolizumab + RAM + paclitaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Mayo Clinic- Minnesota, Rochester, Minnesota
Conditions: Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma
Register for Updates
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755
Recruiting
Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/29/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Moderate Aortic Valve Stenosis
Register for Updates
A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development
NCT06055725
Recruiting
This study will monitor patients during the first year following their stroke. Stroke is a very serious condition where there is a sudden interruption of blood flow in the brain. The main aim of the study will be to find out how many of those who experience their first-ever stroke then go on to develop spasticity that would benefit from treatment with medication. Spasticity is a common post-stroke condition that causes stiff or ridged muscles. The results of this study will provide a standar... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/29/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Spasticity as Sequela of Stroke
Register for Updates
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
NCT05465954
Recruiting
This phase II trial tests the safety and side effects of efineptakin alfa and pembrolizumab in treating patients with glioblastoma that has come back (recurrent). Efineptakin alfa is an immunotherapy drug that works by helping the immune system fight tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving efineptakin alfa and pembrolizumab may ki... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma
Register for Updates
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
NCT06362252
Recruiting
This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung cancer (ES-SCLC) in the first-line (1L) setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Extensive Stage-small Cell Lung Cancer
Register for Updates
Registry for Stage 2 Type 1 Diabetes
NCT06481904
Recruiting
Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin. TZIELD® (teplizumab-mzwv) has been approved to delay onset of stage 3 T1D, by the United States (US) Food and Drug Administration (FDA) for adults and children aged 8 years and older with Stage 2 T1D. The purpose of this study is to collect general... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: Mayo Clinic- Site Number : 8400010, Rochester, Minnesota
Conditions: Type 1 Diabetes
Register for Updates
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
NCT06777316
Recruiting
This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult participants with intrahepatic cholangiocarcinoma (iCCA) or other advanced solid tumors with FGFR2 and/or FGFR3 genetic alternations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Amplification, FGFR2 Gene Short Variants, FGFR3 Gene Fusion/Rearrangement, FGFR3 Gene Amplification, FGFR3 Gene Short Variants, FGFR2 Genetic Alterations, FGFR3 Genetic Alterations, Advanced Solid Tumors
Register for Updates
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT06608927
Recruiting
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Mayo Clinic - Rochester, Rochester, Minnesota
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates